SemperVirens Venture Capital Appoints Henri Cournand as Chief Financial Officer
Cournand brings a distinguished background, with over 17 years of experience as a Cigna executive and, most recently, as Senior Vice President and CFO at Blue Cross Blue Shield of Kansas City. During his tenure there, he also served as CEO of Cobalt Ventures, a strategic Limited Partner of SemperVirens. His extensive experience in financial leadership and strategic growth will be invaluable as SemperVirens continues to expand its impact across the healthcare ecosystem.
In his role as CFO of SemperVirens, Cournand will focus on several key initiatives, including implementing enhanced best practices across the firm's financial operations, leading the SV Healthcare Executive Advisory group and identifying new strategic partners for the firm.
Additionally, he will collaborate closely with portfolio companies in the healthcare and benefits sectors via the SemperSystem™ to unlock ecosystem value and drive revenue growth.
"Henri's deep financial acumen and leadership experience make him an outstanding addition to our team," said
About SemperVirens:
SemperVirens is a specialized venture capital firm launched in 2018 investing in tech startups reshaping the worlds of health, wealth and work at the intersection of the relationship between an employer and its employees. We have a unique value creation model that helps our portfolio companies drive revenue growth via our proprietary network of employers, strategic distribution partners, CHRO advisors, and investors. SemperVirens has over
View original content:https://www.prnewswire.com/news-releases/sempervirens-venture-capital-appoints-henri-cournand-as-chief-financial-officer-302237402.html
SOURCE SemperVirens Venture Capital
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- GAC GS7: Supporting GAC's Global New-energy Expansion
- Target Lowers Prices on Nearly 2,000 Products, Offering Even More Style and Design at an Incredible Value
- Novo's Ozempic® (semaglutide) 2 mg associated with lower risk of major adverse cardiovascular events (death, heart attack, and stroke) in adults with type 2 diabetes compared to switching to Mounjaro
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share